Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 3Gynecologic 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 26Pituitary Neoplasms 11Pheochromocytoma 11Carcinoma, Neuroendocrine 9Thyroid Neoplasms 8Sarcoma 8Thyroid Cancer, Papillary 6Paraganglioma 6Ovarian Neoplasms 5Neuroblastoma 5Adrenocortical Carcinoma 5Small Cell Lung Carcinoma 4Parathyroid Neoplasms 4Pancreatic Neoplasms 4Osteosarcoma 4Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 4Adrenal Gland Neoplasms 4Adenoma, Islet Cell 4Thyroid Carcinoma, Anaplastic 3Stomach Neoplasms 3Prostatic Neoplasms 3Pituitary ACTH Hypersecretion 3Meningioma 3Melanoma 3Head and Neck Neoplasms 3Cushing Syndrome 3Colorectal Neoplasms 3

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intestinal Neoplasms × Endocrine × 30 days × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡